BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND ALDH2, ALDHI, 217, ENSG00000111275, ALDH-E2, P05091, MGC1806, ALDM AND Prognosis
68 results:

  • 1. Clinicopathological, metastatic and prognostic features of stage IV esophageal adenocarcinoma versus squamous cell carcinoma: a SEER database analysis.
    Pan L; Zhang Y; Gao Y; Qiu J
    Chin Clin Oncol; 2024 Feb; 13(1):2. PubMed ID: 38372056
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A novel telomere-related gene prognostic signature for survival and drug treatment efficiency prediction in lung adenocarcinoma.
    Chen H; Liang W; Zheng W; Li F; Pan X; Lu Y
    Aging (Albany NY); 2023 Aug; 15(16):7956-7973. PubMed ID: 37589509
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Expression Pattern and Prognostic Analysis of Branched-Chain Amino Acid Catabolism-Related Genes in Non-Small Cell lung cancer.
    Yao X; Deng Y; Zhou J; Jiang L; Song Y
    Front Biosci (Landmark Ed); 2023 Jun; 28(6):107. PubMed ID: 37395022
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Dissecting the alternation landscape of mitochondrial metabolism-related genes in lung adenocarcinoma and their latent mechanisms.
    Jin X; Liu D; Kong D; Zhou X; Zheng L; Xu C
    Aging (Albany NY); 2023 Jun; 15(12):5482-5496. PubMed ID: 37335087
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Systemic inflammation influences the prognosis of patients with radically resected non-small cell lung cancer and correlates with the immunosuppressive microenvironment.
    Wang P; Wang S; Sun Z; Li H; Zhao Y; Li Y; Yang F; Wang J; Chen K; Qiu M; Li X
    Int J Cancer; 2023 Aug; 153(4):826-842. PubMed ID: 37186387
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. FTO-stabilized miR-139-5p targets ZNF217 to suppress prostate cancer cell malignancies by inactivating the PI3K/Akt/mTOR signal pathway.
    Azhati B; Reheman A; Dilixiati D; Rexiati M
    Arch Biochem Biophys; 2023 Jun; 741():109604. PubMed ID: 37080415
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Respiratory muscle metabolic activity on PET/CT correlates with obstructive ventilatory defect severity and prognosis in patients undergoing lung cancer surgery.
    El Husseini K; Baste JM; Bouyeure-Petit AC; Lhuillier E; Cuvelier A; Decazes P; Vera P; Similowski T; Patout M
    Respirology; 2023 Jun; 28(6):551-560. PubMed ID: 36855939
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Identification of glycolysis genes signature for predicting prognosis in malignant pleural mesothelioma by bioinformatics and machine learning.
    Xiao Y; Huang W; Zhang L; Wang H
    Front Endocrinol (Lausanne); 2022; 13():1056152. PubMed ID: 36523602
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Impact of opioid analgesics on the efficacy of immune checkpoint inhibitors in a lung cancer population.
    Yu X; Zhao L; Song B
    BMC Pulm Med; 2022 Nov; 22(1):431. PubMed ID: 36411438
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Prognostic and clinicopathological significance of CD155 expression in cancer patients: a meta-analysis.
    Zhang D; Liu J; Zheng M; Meng C; Liao J
    World J Surg Oncol; 2022 Oct; 20(1):351. PubMed ID: 36309698
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Successful first-line treatment of simultaneous multiple primary malignancies of lung adenocarcinoma and renal clear cell carcinoma: A case report.
    Ye X; Liu X; Yin N; Song W; Lu J; Yang Y; Chen X
    Front Immunol; 2022; 13():956519. PubMed ID: 35979370
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Wang J; Zhou C; Yao W; Wang Q; Min X; Chen G; Xu X; Li X; Xu F; Fang Y; Yang R; Yu G; Gong Y; Zhao J; Fan Y; Liu Q; Cao L; Yao Y; Liu Y; Li X; Wu J; He Z; Lu K; Jiang L; Hu C; Zhao W; Zhang B; Shi W; Zhang X; Cheng Y;
    Lancet Oncol; 2022 Jun; 23(6):739-747. PubMed ID: 35576956
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Predictors of Survival among Male and Female Patients with Malignant Pleural Mesothelioma: A Random Survival Forest Analysis of Data from the 2000-2017 Surveillance, Epidemiology, and End Results Program.
    Liu B; Niu L; Boscoe F; Lee FF
    J Registry Manag; 2021; 48(3):118-125. PubMed ID: 35413729
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell lung cancer.
    Zheng X; Shao J; Zhou L; Wang L; Ge Y; Wang G; Feng F
    Ther Innov Regul Sci; 2022 Jan; 56(1):155-167. PubMed ID: 34699046
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.
    Oh SY; Kim S; Keam B; Kim TM; Kim DW; Heo DS
    Sci Rep; 2021 Oct; 11(1):19712. PubMed ID: 34611279
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. aldh2 polymorphism rs671 is a predictor of PD-1/PD-L1 inhibitor efficacy against thoracic malignancies.
    Matsumoto A; Nakashima C; Kimura S; Sueoka E; Aragane N
    BMC Cancer; 2021 May; 21(1):584. PubMed ID: 34022841
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. 18F-FDG PET/CT and circulating tumor cells in treatment-naive patients with non-small-cell lung cancer.
    Zhang F; Wu X; Zhu J; Huang Y; Song X; Jiang L
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3250-3259. PubMed ID: 33630146
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor prognosis of Early-Stage lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
    Jiang S; Mao C; Jiang B; Tan Q; Deng B
    Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
    Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
    Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Lipid metabolism gene-wide profile and survival signature of lung adenocarcinoma.
    Li J; Li Q; Su Z; Sun Q; Zhao Y; Feng T; Jiang J; Zhang F; Ma H
    Lipids Health Dis; 2020 Oct; 19(1):222. PubMed ID: 33050938
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 4.